Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced (Unresectable or Metastatic) Melanoma: A Multicentric, Observational Study

NCT03504696 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03504696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03504696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced (Unresectable or Metastatic) Melanoma: A Multicentric, Observational Study
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
December 20, 2016
Completion date
February 20, 2018
Enrollment
400 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma